19 Jul 16

The average age of of the patients 49 years. FLT3-ITD mutation status was determined at a central laboratory to patient enrollment in the study. All 12 patients were treated with Ponatinib as part of that cohort had a history of FLT3-ITD mutation. Documented seven patients had FLT3-ITD at baseline, two had no FLT3 changes at the time of enrollment and baseline FLT3 status could not be determined in three patients.

NotesThe RCN has ample evidence for the verification offered by both the staff perspective and the advice of the occupational health nurses, the evidence highlighted the need to invest in prevention and decent work environments to address some of the health inequalities. Exist in the workplace and build capacity and skills of occupational health services. The RCN also stressed the important link between health of our employees and the quality of patient care.A further list and description of risks, uncertainties and other factors may at Exhibit 99 of of Johnson & Johnson ‘s Form 10 – K for its fiscal year ended 31 December 2006. Copies of this Form 10-K and subsequent filings, are online at and on request from the Company. The company will not obligation to today announced statementsts] result of new information or future events or developments.. Johnson and Johnson Pharmaceutical Research & Development, LLCJohnson & Johnson Pharmaceutical Research & Development, LLC Report problem with is part of Johnson & Johnson, the global large-scale manufacturers of health care products.

Add the most recently completed study ceftobiprole alone was as effective as the combination therapy to elimination of the methicillin-susceptible S. Aureus , MRSA , pyogenic , S. Agalactiae , E. Coli , P. Aeruginosa , Enterobacter spp. Klebsiella pneumoniae and Proteus mirabilis in the the site of infection.